Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by toinv261on Apr 20, 2016 2:44pm

139 Views

Post# 24790150

Life Sciences

To those of interest.

Here is a recent link to Life Sciences with some good discussion of Resverlogix when you scroll down. Also good discussion on prostate but no mention of the Zenith prostate trial even though dosing has started.

https://www.thelifesciencesreport.com/pub/co/4634?utm_source=delivra&utm_medium=email&utm_campaign=TLSR+final+4-20-16

Cheers
Toinv

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?